Status:
COMPLETED
A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
Lead Sponsor:
Celgene Corporation
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
A Phase I Study of CC-5013 in combination with Doxil, Vincristine and Decadron (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
Inclusion
- Understand and voluntarily sign an informed consent form.
- Age greater than 18 years at the time of signing the informed consent form.
- Able to adhere to the study visit schedule and other protocol requirements.
- Diagnosed with active multiple myeloma and be considered to have disease progression after at least 2 cycles of anti-myeloma treatment or have relapsed with progressive disease after treatment.
- Measurable myeloma paraprotein levels in serum (≥ 0.5g/dL) or urine (≥ 0.2 g excreted in a 24-hour collection sample).
- Eastern Cooperative Group (ECOG) Performance Status of 0-2. Performance status of 3 and 4 will be allowed if related to bony disease.
- Bilirubin \< 2 x upper limits of normal (ULN).
- Liver enzymes (ALT or AST) \< 3 x ULN.
- Must have adequate bone marrow function: \* Absolute neutrophil count \> 1,000 cells/mm3 (1.0 x 109/L) \* Platelets ≥ 100,000 cells/mm3 (100 x 109/L) \* Hemoglobin ≥ 8 g/dL
- Must have adequate renal function: creatinine ≤ 2.5 mg/dL.
- Must have 2-d echocardiogram indicating LVEF ≥ 50% within 42 days prior to first dose of study drug.
- Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study drug. WCBP must agree to have pregnancy tests every 4 weeks while on study drug.
Exclusion
- Severe infection requiring intravenous antibiotic treatment.
- Life expectancy of less than 3 months.
- Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer, or other cancer from which the subject has been disease-free for at least 5 years.
- Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia.
- Subjects who have received \> 500mg/m2 of doxorubicin alone, or Doxil® alone, or doxorubicin plus Doxil®.
- Prior treatment with CC-5013.
- Prior development of ≥ grade 2 (NCI CTC) allergic reaction/hypersensitivity while taking thalidomide.
- Prior development of a ≥ grade 3 (NCI CTC) rash or any desquamation while taking thalidomide.
- History of cardiac disease, with New York Heart Association Class II or greater.
- Uncontrolled medical problems such as diabetes mellitus, coronary artery disease, hypertension, unstable angina, arrhythmias), pulmonary, hepatic and renal diseases unless renal insufficiency is felt to be secondary to multiple myeloma.
- Any investigational agent or systemic anti-myeloma therapy within 28 days of the first dose of treatment.
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- Pregnant or lactating females.
- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT00091624
Start Date
March 1 2003
End Date
September 1 2007
Last Update
December 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic Myeloma Program
Cleveland, Ohio, United States, 44195